title: Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
abstract: BACKGROUND
  Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). However, which subgroup of these patients could benefit more from EGFR-TKIs needs to be further explored. In the present study, we explored the predictive factors in such cohorts of patients who received gefitinib.
  
  
  METHODS
  The study included 95 patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment. Multivariate analysis of progression-free survival (PFS) was performed using classification and regression tree (CART) analysis to assess the effect of specific variables on PFS in subgroups of patients with similar clinical features.
  
  
  RESULTS
  The median PFS in patients with EGFR mutation-positive advanced NSCLC who received gefitinib treatment was 13.3 months (95% confidence interval 9.4-17.2). CART analysis showed an initial split on body mass index (BMI); subsequently, three terminal subgroups were formed. The median PFS in the three subsets ranged from 8.2 to 15.2 months, in which the subgroup with a BMI less than or equal to 20.8 kg/m(2) had the longest PFS (15.2 months). In addition, PFS in the EGFR exon 19 mutation group was better than in the other mutation site group (10.3 vs. 8.2 months).
  
  
  CONCLUSIONS
  BMI and exon 19 mutation may be predictors of PFS in patients with EGFR mutation-positive advanced NSCLC who receive gefitinib treatment. Both active EGFR mutation and patient-specific factors may be used to predict the therapeutic efficacy of EGFR-TKIs.
authors.affiliation: Department of Medical Oncology Cancer Institute (Hospital) Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Sun
authors.affiliation: Department of Pathology Rushan County People's Hospital Rushan China.
authors.forename: Xiaoteng
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Medical Oncology Cancer Institute (Hospital) Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Zhai
authors.affiliation: Hexian Affiliated Memorial Hospital Southern Medical University Guangzhou China.
authors.forename: Jingfeng
authors.initials: J
authors.lastname: Guo
authors.affiliation: Department of Medical Oncology Cancer Institute (Hospital) Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
authors.forename: Yutao
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Pathology, Cancer Institute (Hospital) Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
authors.forename: Jianming
authors.initials: J
authors.lastname: Ying
authors.affiliation: Department of Medical Oncology Cancer Institute (Hospital) Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
authors.forename: Ziping
authors.initials: Z
authors.lastname: Wang
keywords: Body mass index (BMI); CART; EGFR active mutation; gefitinib; non‐small‐cell lung cancer
references.citation: Lung Cancer. 2013 Sep;81(3):435-9
references.pmid: 23809059
references.citation: N Engl J Med. 2010 Jun 24;362(25):2380-8
references.pmid: 20573926
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: Oncogene. 2009 Aug;28 Suppl 1:S24-31
references.pmid: 19680293
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4292-302
references.pmid: 12409327
references.citation: Cancer Res. 2005 Sep 1;65(17):7568-72
references.pmid: 16140919
references.citation: Clin Cancer Res. 2004 Jul 15;10(14):4607-13
references.pmid: 15269131
references.citation: Lancet Oncol. 2012 May;13(5):466-75
references.pmid: 22512843
references.citation: J Pharmacokinet Biopharm. 1996 Apr;24(2):153-72
references.pmid: 8875345
references.citation: Eur J Cancer. 2011 Oct;47(15):2331-40
references.pmid: 21802939
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Lancet Oncol. 2010 Feb;11(2):121-8
references.pmid: 20022809
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: Clin Cancer Res. 2009 Aug 15;15(16):5267-73
references.pmid: 19671843
references.citation: J Thorac Oncol. 2010 Sep;5(9):1404-9
references.pmid: 20651613
references.citation: Int J Hematol. 2009 Jun;89(5):642-8
references.pmid: 19396513
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: Cancer Prev Res (Phila). 2008 Jun;1(1):39-44
references.pmid: 19138934
references.citation: J Thorac Oncol. 2013 Sep;8(9):1148-55
references.pmid: 23945384
references.citation: Lancet Oncol. 2015 Feb;16(2):141-51
references.pmid: 25589191
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3815-25
references.pmid: 12228201